CD8A and neoplasm: designed immune agonist-anchoring liposomes to co-deliver IL-2 and an anti-CD137 antibody, which promoted tumor infiltration of CD8+ T cells, enhanced cytokine and granzyme secretion, and elicited strong antitumor responses while reducing systemic toxicity (135).